Summary
AstraZeneca's rumored takeover of Bristol Myers Squibb appears to be off, following reports of preliminary talks and a subsequent denial of ongoing discussions. AstraZeneca's shares initially plunged on the news of talks but saw a mini-relief rally after Reuters reported no current discussions, leaving shareholders seeking clarification.